Answers are grounded in this paper and cite their sources.
In the past, therapeutic options in patients with gastroesophageal reflux disease (GERD) were limited, and the aim of medical therapy was only to control the severity and duration of symptom episodes. Although medical therapy for GERD has improved remarkably since the introduction of the proton pump inhibitors (PPIs) in the late 1980s, some patients still do not respond as expected to currently available therapy. Despite twice daily dosing of PPIs, reflux symptoms may persist, new symptoms may occur or be unmasked, and esophagitis may fail to heal. Some of these patients may not take their medications, well-defined pharmacokinetic factors or genetic polymorphisms may be contributing, nonacid reflux may be the culprit or their esophagitis and/or symptoms may not be due to acid reflux. Management of the difficult-to-treat (refractory) reflux patient can be a challenge for the clinician. Traditionally, patients with GERD symptoms no longer undergo initial endoscopy, but rather are given a 4–8-week trial of a PPI in the morning. Failure to respond occurs in 25–42% of patients, thus placing them in a more difficult-to-manage classification.1 At this point, the physician should ensure patient compliance and review timing of the PPI dose (0.5–1.0 h before meals). One recent study found that nearly 70% of primary physicians and 20% of gastroenterologists gave the PPI dose at bedtime or did not believe the relationship to meals was important.2 Possibly switching to a second generation PPI (i.e. pantoprazole, esomeprazole) is reasonable at this point. This was recently confirmed in a multicenter study of patients with persistent heartburn symptoms while receiving lansoprazole 30 mg once daily.3 Switching to a single dose of esomeprazole (40 mg) was as effective as twice daily lansoprazole in relieving heartburn complaints over 8 weeks of therapy. However, most physicians increase to twice daily dosing (before breakfast and dinner) with up to 25% of patients responding.4 Those doing no better fall into the ‘refractory GERD’ category and are the subject of this discussion. The first investigation to perform in the refractory GERD patient (Fig. 1), if not done earlier, is an upper endoscopy to exclude the possibilities of refractory peptic ulcer disease or, less likely, gastric cancer, and identify the presence of ‘acid resistant’ esophagitis. Although less common that the nonerosive alternative, these patients represent several well-defined diseases which can be identified by careful history, physical exam, and blood tests. Esophageal pH testing on twice daily PPI usually confirms excellent acid control and supports a nonacid etiology for their esophagitis. Algorithm for the evaluation of patients with refractory GERD. In our experience at the Cleveland Clinic, the ‘refractory GERD’ patient with a normal endoscopy is much more common. Esophageal and gastric pH testing on twice daily PPI therapy is our next study of choice. However, our experience found that only 7% of patients with classic heartburn symptoms and 1% of subjects with atypical reflux symptoms still have abnormal amounts of acid reflux.5 Although currently popular today to suggest these patients have nonacid GER, other alternatives need to be considered, and may be more common. For example, these patients could have ‘missed’ acid reflux not picked up on a single-day investigation (25% of cases in the Bravo capsule experience) or the pH probe may be missing distal acid reflux confined to just above the esophogastric junction. Alternatively, they may have a non-reflux diagnosis such as achalasia, gastroparesis, or the nebulous term ‘functional heartburn.’ Currently, available technology such as impedance, Bravo capsule, esophageal manometry and gastric scintography, may help us identify many of these patients. As previously noted, patients on twice daily PPIs rarely have important esophagitis unless non-compliance is an issue or they have a hypersecretory state, such as the Zollinger–Ellison syndrome. Diagnoses to consider include (Table 1): Differential diagnoses for refractory GERD patients with esophagitis GERD, gastroesophageal reflux disease; ZES, Zollinger-Ellison syndrome. Differential diagnoses for refractory GERD patients with esophagitis GERD, gastroesophageal reflux disease; ZES, Zollinger-Ellison syndrome. Pill-induced esophagitis Pills may be a complicating factor in young patients or the elderly.6,7 In younger patients, symptoms are acute and often associated with odynophagia, chest pain and dysphagia. In the elderly, complaints may be more chronic and complicating an underlying esophageal motility disorder or subtle stricture. Endoscopy may identify esophagitis often characterized by one or more discrete ulcers with normal surrounding mucosa. At other times, diffuse inflammation, thick whitish exudates, pseudotumors, fibrotic strictures and even perforation have been reported. The most common site of injury is the junction of the proximal and middle third of the esophagus where peristaltic amplitude is relatively low and where the esophagus may be compressed by the aortic arch. The distal esophagus may be involved, sometimes with sparing of the squamocolumnar junction, to help in differentiating from reflux esophagitis. Common drugs include doxycycline and tetracycline (especially in young people), alendronate, naproxen, potassium chloride, ascorbic acid, quinidine and ferrous sulfate. In a recent large series,7 one-third of the cases were due to aspirin or non-steroidal anti-inflammatory drugs. The majority of patients improve within 1 week by stopping the offending agent and treatment with PPIs and/or sucralfate. Patients who develop strictures may require repeated dilatations. Skin diseases A variety of dermatologic diseases are associated with esophageal involvement. Those most likely to cause an intractable esophagitis syndrome include epidermolysis bullosa acquisita, pemphigus vulgaris, cicatrical pemphigoid, and lichen planus.8 These are generally considered uncommon autoimmune diseases. Patients are usually middle-aged women, may have associated dysphagia from proximal esophageal strictures, and associated skin, oral mucosa and anogenital disease may not be obvious. Endoscopy reveals diffuse erythemia, blistering of superficial mucosa which easily peels away from the submucosa, whitish nodules/plaques and proximal stricture disease. Rarely, a cast of the entire esophagus lining is vomited up and is know as esophagitis dessicans superificialis. Biopsies of involved and uninvolved esophageal mucosa should be sent for direct and indirect immunofluorescence to make an accurate diagnosis. In suspected lichen planus, biopsies of the whitish nodules often reveal a dense histocytic infiltrate. Referral to a dermatologist should be made for immunosuppressive therapy including prednisone, dapsone, azathioprine, cyclophosphamide and tacrolimus. Some patients require frequent esophageal dilation for their stricture disease; intralesional corticosteroid injection may also be helpful.9 Acid hypersecretors The hypersecretion of acid may impair the efficacy of PPIs, but acid hypersecretion is uncommon in GERD patients. Patients with Zollinger-Ellison syndrome (ZES) have endoscopically visible esophagitis in 30–45%, some with difficult to manage esophageal strictures. When PPIs are administered (usually twice daily) to lower gastric acid secretion to < 10 mEq/h, over two-thirds of patients will have symptom reduction and healing of esophagitis. Some patients with recalcitrant strictures may need their gastric acid output lowered to < 1 mEq/h to alleviate the need for frequent esophageal dilations.10 In one study, predictors for esophagitis in ZES patients included vomiting, low LES pressure and obesity.11 Genotypic differences PPIs are mainly metabolized by the hepatic cytochrome P-450 2C enzymes, and although pharmacokinetic interactions at this level are uncommon, there is considerable genetic variation in enzyme capacity. Recent reports reveal that plasma concentrations and acid-inhibitory effects on omeprazole and lansoprazole depend on the CYP2C19 genotype. Rapid metabolizers show lower effect of PPIs on gastric acidity and esophagitis healing than slow or intermediate metabolizers.12 This genetic propensity to be a rapid metabolizer of PPIs is most common in the Asian population (12–20%) and infrequent in Caucasians (3–6%). Unlike other PPIs, a recent study suggests esomeprazole may have preferred metabolism through another pathway mediated by CYP3A4.13 To date, all studies have been done with single doses of PPIs; it is unknown if twice daily dosing will overcome this problem. Eosinophilic esophagitis An increasingly common diagnosis, patients with eosinophilic esophagitis are usually young, male and present with dysphagia often with a history of food impaction.14 The diagnosis is suggested by endoscopic findings of multiple rings, longitudinal furrows, or pinpoint white exudates. Biopsies should be done of the proximal and distal esophagus where histology will show > 20–25 eosiniphils/high power field. Peripheral eosinophilia is uncommon. The pathogenesis of eosinophilic esophagitis is unknown. Some suggest it is precipitated by foods (i.e. shellfish, avocado, peanuts) and aeroallergens that stimulate a Th2 cytokine response,15 while other data suggest some patients have an atypical variant of GERD.16 Eosinophils and symptoms will improve with inhaled steroids, fluticasone propionate twice daily (before breakfast and dinner) for 6 weeks.17 To ensure adequate delivery to the esophagus and not the lungs, a spacer should not be used. The patient should be instructed to inspire deeply and at the same moment, depress the inhaler and swallow the aerosol. The patient should rinse the mouth out with water and avoid food or drink for 2–3 hours. If this fails to resolve symptoms, other therapies include a leukotriene D4 antagonist (montelukast 10–40 mg/day by gradual dose escalation) or oral steroids (prednisone 30 mg/day for 2 weeks and taper over 6 weeks). Oral candidiasis may complicate steroid therapy. Other patients do well with PPIs and careful bougie dilation. The natural history of eosinophilic esophagitis is poorly understood.18 The most common endoscopic finding in patients with ‘refractory GERD’ is a normal esophagus, often without an hiatal hernia or at best, a small hernia. Here the issue is much more problematic and less likely to lead to a satisfactory outcome. In our experience, these patients on twice daily PPIs have a less than 10% chance of having an abnormal esophageal reflux profile for acid,5 thus nonacid GER or ‘missed’ GER needs to be considered. However, these diagnoses are limited by treatment alternatives and clear understanding of their importance based on current technology. Other potential etiologies such as achalasia and gastroparesis should always be evaluated and excluded (Table 2). Differential diagnoses for refractory GERD patients without esophagitis GERD, gastroesophageal reflux disease. Differential diagnoses for refractory GERD patients without esophagitis GERD, gastroesophageal reflux disease. Nocturnal gastric acid breakthrough (NAB) Persistent gastric acidity at night despite being on twice daily PPI therapy is common (60–80% of patients) and probably important in protecting the GI tract from bacterial contamination and nitrosamines. However, this natural phenomenon allows the potential for breakthrough acid reflux at night when the esophagus is least likely to protect itself. Studies in healthy volunteers found that NAB was nearly eliminated with the addition of H2RAs (ranitidine 150 mg or 300 mg at bedtime) to omeprazole 20 mg twice daily.19 However, my group attempted to replicate this study in 40 subjects (20 healthy volunteers and 20 GER patients) finding identical results at one day on a bedtime H2RA added to a twice daily PPI regimen, but by 1 and 4 weeks, the nighttime gastric acid exposure had returned to the values observed on PPIs alone.20 This is secondary to the phenomenon of tolerance to H2RAs which occurs with continuous usage over 1 week.21 Placebo-controlled studies have not tested the symptomatic efficacy of H2RAs at night for control of nocturnal reflux symptoms. Although not formally tested, possibly intermittent H2RA use when the patient is exposed to refluxogenic stimulus (i.e. after a large fatty meal or night of cocktails) may be the optimal approach to minimizing the chance of developing drug tolerance. Non-acid GER New technology permits the measurement of nonacidic reflux in an ambulatory state. Most often this represents previously ingested food and least frequently reflux of duodenal contents (i.e. bile reflux). Impedance measures the movement of liquids and gases in the esophagus; combined with pH monitoring it can identify nonacid reflux.22 Bilitec monitoring measures reflux of bilirubin, a surrogate for bile reflux, which helps to better characterize the origin of nonacid reflux.23 Several studies on twice daily PPI therapy suggest that 20–40% of patients have nonacid reflux, often containing bile, which may be contributing to their symptoms.24,25 In the impedance studies,26 the low side of the range represents subjects with abnormal quantities of nonacid reflux, usually food after a meal, while the higher values are obtained by including patients with a positive symptom relationship (symptom index) with or without pathological amounts of nonacid reflux. Although one study found baclofen (5 mg thrice daily increased slowly to 20 mg thrice daily) decreases nonacid reflux and improves symptoms, little long-term efficacy or safety data is available.27 Other than for clear symptoms of regurgitation, the role of antireflux surgery in nonacid reflux has not been carefully studied. Missed GER Acid GER may be missed by traditional tube catheters because the phenomenon does not occur every day, the pH probe is placed too proximal in the esophagus or the noxious effect of the nasal catheter limits eating and activity, giving a false-negative test. Wireless pH monitoring (Bravo capsule) allows measurement of acid reflux for at least 2 days, with initial studies finding that at least 25% of patients do not reflux on two consecutive days.28 The Bravo capsule allows pH monitoring in unusual situations (heavy exercising, swimming) and potentially can collect pH data until the capsule dislodges (usually after 5–7 days) as long as the data is downloaded every 48 h and the batteries are changed. Traditionally, the pH probe is placed 5 cm above the proximal border of the lower esophageal sphincter, despite the interesting observation that reflux esophagitis infrequently extends this far proximal to the EG junction. A recent study using the wireless capsule found that 24 acid exposure in 11 endoscopy-negative dyspeptic patients was greater 5 mm above the squamo-columnar junction compared to the conventional 5 cm (11.7%vs. 1.8%; P < 0.001).29 Whether the possibility of ‘missed’ acid reflux in patients on twice daily PPIs is contributing to their intractable symptoms is unknown at this time. Wrong diagnosis Achalasia with a minimally dilated esophagus may occasionally mimic GERD. This can easily be diagnosed with esophageal manometry. Patients with epigastric pain, early satiety, postprandial abdominal bloating, nausea and vomiting may have delayed gastric emptying contributing or worsening their reflux disease. We found this a common problem in difficult-to-manage reflux patients where regurgitation rather than heartburn is a major complaint. Finally, some patients may have the nebulous diagnosis ‘functional heartburn’, a poorly described syndrome in search of a treatment.30 Patients with refractory GERD, defined as symptoms unresponsive to twice daily PPIs after 4–8 weeks of treatment, should first undergo upper endoscopy to exclude ulcer disease, cancer and identify the presence of esophagitis. Refractory esophagitis suggests a pill injury, a skin disease with associated esophageal involvement, or the syndrome of eosinophilic esophagitis. Less likely are a hypersecretory syndrome (ZES) or genotypic difference in metabolism of PPIs. Refractory reflux syndromes with a normal endoscopic exam are more problematic and require further testing including measurement of nonacid reflux, prolonged pH monitoring over 48 h or more, esophageal manometry, and gastric function tests. Although the diagnosis of nonacid reflux is popular today, the appropriate medical and surgical treatments are poorly defined. Atypical presentation of achalasia and gastroparesis should not be overlooked.
No takes yet. Share an insight, caveat, or question.
Joel E. Richter (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: